|
Journal of Lipid Research, Vol. 42, 1239-1249, August 2001
Copyright © 2001 by Lipid Research, Inc.
Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia
Hannia Camposa,
Dan Perlova,
Christina Khooa, and
Frank M. Sacksa,b
a Department of Nutrition, Harvard School of Public Health, Boston, MA 02115
b Channing Laboratory, Departments of Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, MA 02115
Correspondence to:
Hannia Campos, To whom correspondence should be addressed., hcampos{at}hsph.harvard.edu (E-mail)
Apolipoprotein (apo) E and apoC-III concentrations in VLDL and LDL are associated with coronary heart disease. We studied the relationship between apoE and apoC-III and the abnormal concentrations and distribution of apoB lipoproteins in 10 hypercholesterolemic and 13 hypertriglyceridemic patients compared with 12 normolipidemic subjects (mean age, 45 years). Sixteen distinct types of apoB lipoprotein particles were separated by first using anti-apoE and anti-apoC-III immunoaffinity chromatography in sequence and then ultracentrifugation [light VLDL, dense VLDL, IDL, and LDL, with apoE with or without apoC-III (E+C-III+, E+C-III-) or without apoE with or without apoC-III (E-C-III+, E-C-III-)]. The concentrations of VLDL particles with apoC-III (E+C-III+, E-C-III+) were increased in the hypertriglyceridemic group compared with the hypercholesterolemic and normolipidemic groups. These particles were the most triglyceride rich of the particle types, and their triglyceride content was twice as high in hypertriglyceridemics compared with the other two groups. Hypertriglyceridemics had a similar concentration of total E-C-III- particles compared with normolipidemics, but the E-C-III- particles were distributed more to VLDL and IDL than to LDL. Hypercholesterolemics, in contrast, were distinguished from the normolipidemic group by 2-fold higher concentrations of apoB lipoproteins without apoE or apoC-III (E-C-III-), mainly LDL, which had high cholesterol content. Nonetheless, both normolipidemics and hypercholesterolemics had apoC-III-containing VLDL, which comprised 68% and 43% of their total VLDL particles. E+C-III- particles were a minor type, comprising <10% of particles in all lipoproteins and patient groups.
Therefore, VLDL particles with apoC-III may play a central role in identifying the high risk of coronary heart disease in hypertriglyceridemia, but their substantial prevalence in normolipidemics may be of clinical significance as well. Campos, H., D. Perlov, C. Khoo, and F. M. Sacks. Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia. J. Lipid Res. 2001. 42: 1239;1249.
Supplementary key words:
metabolism, cholesterol, triglyceride

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. O. Mendivil, C. Zheng, J. Furtado, J. Lel, and F. M. Sacks
Metabolism of Very-Low-Density Lipoprotein and Low-Density Lipoprotein Containing Apolipoprotein C-III and Not Other Small Apolipoproteins
Arterioscler Thromb Vasc Biol,
February 1, 2010;
30(2):
239 - 245.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. B. van Schalkwijk, A. A. de Graaf, B. van Ommen, K. van Bochove, P. C. N. Rensen, L. M. Havekes, N. C. A. van de Pas, H. C. J. Hoefsloot, J. van der Greef, and A. P. Freidig
Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size
J. Lipid Res.,
December 1, 2009;
50(12):
2398 - 2411.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Hiukka, M. Stahlman, C. Pettersson, M. Levin, M. Adiels, S. Teneberg, E. S. Leinonen, L. M. Hulten, O. Wiklund, M. Oresic, et al.
ApoCIII-Enriched LDL in Type 2 Diabetes Displays Altered Lipid Composition, Increased Susceptibility for Sphingomyelinase, and Increased Binding to Biglycan
Diabetes,
September 1, 2009;
58(9):
2018 - 2026.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kawakami, M. Osaka, M. Aikawa, S. Uematsu, S. Akira, P. Libby, K. Shimokado, F. M. Sacks, and M. Yoshida
Toll-Like Receptor 2 Mediates Apolipoprotein CIII-Induced Monocyte Activation
Circ. Res.,
December 5, 2008;
103(12):
1402 - 1409.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-C. Fruchart, F. M Sacks, M. P Hermans, G. Assmann, W V. Brown, R. Ceska, M J. Chapman, P. M Dodson, P. Fioretto, H. N Ginsberg, et al.
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients
Diabetes and Vascular Disease Research,
November 1, 2008;
5(4):
319 - 335.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kawakami, M. Osaka, M. Tani, H. Azuma, F. M. Sacks, K. Shimokado, and M. Yoshida
Apolipoprotein CIII Links Hyperlipidemia With Vascular Endothelial Cell Dysfunction
Circulation,
August 12, 2008;
118(7):
731 - 742.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Zheng, C. Khoo, J. Furtado, K. Ikewaki, and F. M Sacks
Dietary monounsaturated fat activates metabolic pathways for triglyceride-rich lipoproteins that involve apolipoproteins E and C-III
Am. J. Clinical Nutrition,
August 1, 2008;
88(2):
272 - 281.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Millar, M. E. Brousseau, M. R. Diffenderfer, P. H. R. Barrett, F. K. Welty, J. S. Cohn, A. Wilson, M. L. Wolfe, C. Nartsupha, P. M. Schaefer, et al.
Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism
J. Lipid Res.,
March 1, 2008;
49(3):
543 - 549.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Zheng, C. Khoo, K. Ikewaki, and F. M. Sacks
Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions
J. Lipid Res.,
May 1, 2007;
48(5):
1190 - 1203.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Lamant, F. Smih, R. Harmancey, P. Philip-Couderc, A. Pathak, J. Roncalli, M. Galinier, X. Collet, P. Massabuau, J.-M. Senard, et al.
ApoO, a Novel Apolipoprotein, Is an Original Glycoprotein Up-regulated by Diabetes in Human Heart
J. Biol. Chem.,
November 24, 2006;
281(47):
36289 - 36302.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kawakami, M. Aikawa, P. Alcaide, F. W. Luscinskas, P. Libby, and F. M. Sacks
Apolipoprotein CIII Induces Expression of Vascular Cell Adhesion Molecule-1 in Vascular Endothelial Cells and Increases Adhesion of Monocytic Cells
Circulation,
August 15, 2006;
114(7):
681 - 687.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Zheng, S. J. Murdoch, J. D. Brunzell, and F. M. Sacks
Lipoprotein Lipase Bound to Apolipoprotein B Lipoproteins Accelerates Clearance of Postprandial Lipoproteins in Humans
Arterioscler Thromb Vasc Biol,
April 1, 2006;
26(4):
891 - 896.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kawakami, M. Aikawa, P. Libby, P. Alcaide, F. W. Luscinskas, and F. M. Sacks
Apolipoprotein CIII in Apolipoprotein B Lipoproteins Enhances the Adhesion of Human Monocytic Cells to Endothelial Cells
Circulation,
February 7, 2006;
113(5):
691 - 700.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Davidsson, J. Hulthe, B. Fagerberg, B.-M. Olsson, C. Hallberg, B. Dahllof, and G. Camejo
A proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes
J. Lipid Res.,
September 1, 2005;
46(9):
1999 - 2006.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. E. Chiuve, L. A. Martin, H. Campos, and F. M. Sacks
Effect of the Combination of Methyltestosterone and Esterified Estrogens Compared with Esterified Estrogens Alone on Apolipoprotein CIII and Other Apolipoproteins in Very Low Density, Low Density, and High Density Lipoproteins in Surgically Postmenopausal Women
J. Clin. Endocrinol. Metab.,
May 1, 2004;
89(5):
2207 - 2213.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. M. Sacks and H. Campos
Low-Density Lipoprotein Size and Cardiovascular Disease: A Reappraisal
J. Clin. Endocrinol. Metab.,
October 1, 2003;
88(10):
4525 - 4532.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-J. Lee, H. Campos, L. A. Moye, and F. M. Sacks
LDL Containing Apolipoprotein CIII Is an Independent Risk Factor for Coronary Events in Diabetic Patients
Arterioscler Thromb Vasc Biol,
May 1, 2003;
23(5):
853 - 858.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. R. Blackett, R. Germany, B. Sambo, and P. Alaupovic
Apolipoprotein C-III Bound to Apolipoprotein B-containing Lipoproteins in Obese Girls
Clin. Chem.,
February 1, 2003;
49(2):
303 - 306.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. K. Berneis and R. M. Krauss
Metabolic origins and clinical significance of LDL heterogeneity
J. Lipid Res.,
September 1, 2002;
43(9):
1363 - 1379.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|